Abstract: A method for assessing suicide risk for a human subject including receiving recorded voice data of the subject; and classifying the subject as suicidal or non-suicidal based upon a computerized analysis of one or more nonverbal characteristics of the speech data, especially features associated with a breathy phonation type. The analysis of the nonverbal characteristics of the voice data can include an analysis of acoustic characteristics of speech, and/or an analysis of prosodic and voice quality-related features of the voice data. Related apparatus, systems, techniques and articles are also described.

Abstract: The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGFR-1 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGFR-1 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGFR-1 gene.

Abstract: Described is a coated, (partly) lithiated graphite powder characterized in that it has been produced in a non-electrochemical process from metallic lithium and graphite in powder form and has been stabilized outside an electrochemical cell by application of a coating layer; and a galvanic cell comprising a cathode, a lithium-conductive electrolyte-separator system and an anode comprising a coated, (partly) lithiated graphite powder, where the (partial) lithiation and the coating of the graphite powder are performed non-electrochemically outside the galvanic cell (ex situ).

Abstract: The invention relates to a galvanic cell containing a cathode, a lithium-conductive electrolyte separator system, and a synthetic graphite-containing anode. In the manufacture of the cell (i.e. prior to the first charging cycle), the anode contains or consists of a (partially) lithiated graphite powder which is produced from synthetic graphite and lithium powder in a non-electrochemical manner. The invention also relates to a method for (partially) lithiating synthetic graphite in an electroless manner. The invention is characterized in that the particulate synthetic graphite is (partially) lithiated in an electroless manner after mixing with particulate lithium metal powder and by means of a mixing and/or milling process, thereby forming Li graphite intercalates of the composition LiCx (mit x=6?600).

Abstract: The present invention relates to a novel crystalline modification of fipronil, to a process for the preparation of the same, to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification and to their use for combating pests and parasites.

Abstract: The present invention relates to a novel crystalline form A of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione. The invention also relates to a process for the production of this crystalline form and formulations for plant protection which contains the novel crystalline form of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione.

Abstract: The present invention relates to a novel crystalline form B of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione The invention also relates to a process for the production of this crystalline form and formulations for plant protection which contains the novel crystalline form of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione.

Abstract: The present invention relates to methods for providing an active lithium reservoir to reduce the irreversible initial losses and as a general lithium source of or for electrode materials and lithium batteries, and a powdered lithium-donating material having an electrochemical potential of 0.5 and 2 V vs. Li/Li+, which has been selected from the group of lithium hydride, lithium amide, lithium imide and tetra-lithium ammonium hydride, is used as a general lithium source.

Abstract: A method for assessing suicide risk for a human subject including receiving recorded voice data of the subject; and classifying the subject as suicidal or non-suicidal based upon a computerized analysis of one or more nonverbal characteristics of the speech data, especially features associated with a breathy phonation type. The analysis of the nonverbal characteristics of the voice data can include an analysis of acoustic characteristics of speech, and/or an analysis of prosodic and voice quality-related features of the voice data. Related apparatus, systems, techniques and articles are also described.

Abstract: The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of E-selectin, ICAM-1 or VEGFR-3 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.

Abstract: Method for compensating illumination deficiencies in microscopic “shape from focus (SFF)”, wherein firstly the reflectance of the scene is estimated by way of a projector-camera system and then microscopic “shape from focus (SFF)” is applied to a stack of reflectance maps rather than to the original image data.

Abstract: A method for monitoring a nitrogen oxide storage catalytic converter (NSC) in the exhaust gas duct of an internal combustion engine which is operated at least temporarily in a lean fashion, wherein during a lean mode of the internal combustion engine nitrogen oxides from the exhaust gas are stored by the nitrogen oxide storage catalytic converter, wherein during a regeneration phase of the nitrogen oxide storage catalytic converter the internal combustion engine is operated in a rich fashion, and as a result the nitrogen oxides stored in the nitrogen oxide storage catalytic converter are removed, and wherein an exhaust gas component or exhaust gas characteristic variable which is characteristic of the profile of the regeneration is detected during the regeneration phase by means of an exhaust gas probe.

Abstract: The present invention relates to a novel crystalline form B of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione The invention also relates to a process for the production of this crystalline form and formulations for plant protection which contains the novel crystalline form of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione.

Abstract: A method is presented for controlling an internal combustion engine (10), which includes an exhaust gas system (12) having an exhaust gas aftertreatment component (22) that temporarily stores exhaust gas constituents and can be regenerated, wherein an expected value for a temperature of the exhaust gas aftertreatment component (22) is formed as a function of an increase in temperature, which arises as a result of exothermal reactions during the duration of an operating mode (BA2) of the internal combustion engine (10) which is set for the regeneration of said exhaust gas aftertreatment component (22), wherein the expected value is compared with an upper threshold value (T_max) and the control of said internal combustion engine (10) is changed when the threshold value (T_max) is exceeded, such that an expected value formed while taking the changed control into account does not exceed said threshold value (T_max).

Abstract: The present invention relates to a novel crystalline form A of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione. The invention also relates to a process for the production of this crystalline form and formulations for plant protection which contains the novel crystalline form of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione.

Abstract: The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGFR-1 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGFR-1 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGFR-1 gene.

Abstract: The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.

Abstract: The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the overall survival and/or progression-free survival of the patient.

Abstract: The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGF promoter gene and/or VEGFR2 gene.

Abstract: The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.